Stille completes the acquisition of Fehling Instruments

Stille AB (publ) has successfully completed the previously announced acquisition of the German instrument provider Fehling (Fehling Instruments GmbH & Co. KG, Fehling Verwaltungs GmbH, and associated subsidiaries, collectively referred to as "Fehling"). All conditions for the transaction and acquisition have now been met. As previously communicated, Stille has paid 36 million euros in cash upon the completion of the acquisition on a debt-free and cash-free basis. The acquisition is financed through the previously announced targeted issuance of SEK 425 million.

Fehling develops and sells high-quality medical instruments, focusing on demanding specialties such as open and minimally invasive cardiac, thoracic, neuro, and spine surgery. Fehling has a global sales presence through a combination of direct sales and distributors. Through the acquisition, Stille significantly expands its product range, research and development capacity, and global presence.

Torshälla, January 25th, 2024.

For more information, please contact:

Torbjörn Sköld
CEO and President
+46 (0)70 316 63 91 | torbjorn.skold@stille.se

Stille AB (publ) publ) develops, manufactures and markets medical devices for surgeons across the world. Stille was founded in 1841 and is one of the world’s oldest medical device companies. Stille’s main business areas are surgical instruments and c-arm tables. Stille’s surgical instruments are mostly used during different kinds of open surgery. During minimal invasive procedures. the c-arm tables imagiQ2 and Medstone are key products. The company has a strong brand and products of a renowned high-quality. The share is listed on First North Growth Market under the acronym “STIL” with Eminova AB as Certified Adviser, Eminova Fondkommission AB, + 46 8 684 211 10, adviser@eminova.se. For more information, visit www.stille.se.